Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy

Fig. 2

The cumulative incidence rates of rebleeding at different time points in the entire cohort (N = 1139; 216 in the non-antiviral group vs. 923 in the antiviral group) and propensity score matched cohort (N = 348; 174 in the non-antiviral group vs. 174 in the antiviral group). The entire cohort: a, 1 year; b, 2 years; c, 3 years; d, 5 years. The PS matching cohort: e, 1 year; f, 2 years; g, 3 years; h, 5 years

Back to article page